|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date20 Jul 2023 |
Target- |
MechanismImmunostimulants |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date31 Aug 2007 |
A Phase 1 Randomized, Blinded, Placebo Controlled, Dose-Escalation and Dosing Regimen Selection Study to Evaluate the Safety and Immunogenicity of rVSV-Vectored Lassa Virus Vaccine in Healthy Adults at Multiple Sites in West Africa
100 Clinical Results associated with Emergent Product Development Gaithersburg, Inc.
0 Patents (Medical) associated with Emergent Product Development Gaithersburg, Inc.
100 Deals associated with Emergent Product Development Gaithersburg, Inc.
100 Translational Medicine associated with Emergent Product Development Gaithersburg, Inc.